Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
There's a meeting today to vote through the 50p rex shares.
Once that's done and they are issued tomorrow it can start moving.
It's the magic of placings whatever the price of the placing is the SP sits at it until the shares are issued.
I see Derek who told us he wasn't going to post until summer is well into his disruptive trolling this weekend thank goodness for the filter button. Although it's still a green box at the end of all the threads.
Bang on DTW.
Exactly, we need a frank and truthful update. Like you I believe the trial is still going well, why would it not be?
Just a reminder from the data rns for those who would try and tell us that ava6000 has stopped working.
1. The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended. The data show that the pre|CISIONTM modification is cleaved specifically by Fibroblast Activation Protein (FAP), an enzyme present in high concentrations in many solid tumours compared with healthy tissue. In the case of AVA6000, this targets the release of doxorubicin to the tumour microenvironment, concentrating the active cytotoxic drug within the tumor microenvironment and limiting systemic exposure to the chemotherapy.
2. AVA6000 has significantly improved the safety and tolerability of doxorubicin. A significant reduction in the frequency and severity of the known doxorubicin toxicities has been observed across the dosing range. A maximum tolerated dose has not been reached in the three-weekly dose escalation study despite dosing approximately 3.5x the normal level of doxorubicin in the highest and final dose cohort in this part of the Phase 1a study.
3. AVA6000 has shown encouraging preliminary clinical signs of anti-tumour activity. Preliminary results in the Phase 1a trial demonstrate activity of AVA6000 in patients with tumours with high FAP activity, validating the mechanism of action of AVA6000. For example, a 59-year-old male patient with Undifferentiated Pleomorphic Sarcoma (UPS) has shown a reduction in tumour volume of 65% with a duration of response >6 months and ongoing. A number of other patients with different cancer types have shown smaller ongoing reductions in tumour volume or stable disease.
I'd be very surprised if AS sees anything wrong in what's gone on and he's certainly not going to create one of his explainer videos to give reasons why.
There certainly no way he'll step down off his own back.
On a positive note though they are now funded for a year possibly two.